Novartis raises 2025 forecast after strong Q1 momentum Novartis has today released a more optimistic full-year earnings forecast, citing the strong growth of drugs such as Leqvio, Kisqali and Kesimpta during the first quarter. Business • 29 Apr
Novartis raises 2025 forecast after strong Q1 momentum Novartis has today released a more optimistic full-year earnings forecast, citing the strong growth of drugs such as Leqvio, Kisqali and Kesimpta during the first quarter. Business • 29 Apr
